Abelchia, also termed the inability to belch syndrome, is an increasingly recognized upper esophageal sphincter (UES) disorder characterized by retrograde cricopharyngeal dysfunction (RCPD). This disorder is highly relevant to gastroenterologists since presentation consists of common upper gastrointestinal symptoms including chest pain, gurgling noises in the chest, abdominal pressure, and bloating, often misattributed to alternate foregut disorders. Abelchia is thought to result from absent or incomplete UES relaxation in response to retrograde esophageal air distension, causing esophageal air trapping, despite preserved anterograde swallowing-related UES relaxation. The diagnosis is suspected based on clinical presentation and absence of alternate esophageal structural/motor disorders and supported by high-resolution impedance manometry with carbonated beverage challenge. Injection of botulinum toxin into the UES during rigid esophagoscopy is the mainstay of treatment, though data supporting this are largely derived from case series. Symptom benefit typically outlasts the general duration of efficacy of botulinum toxin, suggesting retraining of retrograde UES relaxation and the ability to belch. Consequently, behavioral therapy has been also reported to be of benefit. Randomized trials, standardized diagnostic criteria, and long-term outcome studies are lacking. This review summarizes the evolving literature on abelchia with emphasis on clinical presentation, diagnostic evaluation, differential diagnosis, treatment, and the role of gastroenterologists in identifying this underrecognized disorder.